What is CRMD's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for CRMD.

Stock Ratings / Health Care / CRMD / options

KMDA (46) BLSM (42) PRTA (23) PHAT (33) ⌘ Pro Terminal →

CorMedix Inc. (CRMD) Options Positioning, Max Pain & Unusual Sweeps

$5.39 -5.36% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.33

CorMedix Inc. (CRMD) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C- • HOLD / WATCH Cap $443.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CRMD Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CRMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, CorMedix Inc. (NASDAQ: CRMD) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $5.39 (-5.36% 1D, market cap $443.9M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 15/20. Across 1016 tracked Health Care issuers, CRMD ranks #173 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CRMD compare to KMDA and BLSM in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CRMD carries a Roarable C- (59/100 RQD), trailing P/E of 3.7x, gross margin of 88.5%, and ROIC of 45.5%. By comparison, KMDA (Kamada Ltd.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $444.4M) and BLSM (BlossomHill Therapeutics Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC —, cap $437.0M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while CRMD leads on capital efficiency (45.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CRMD?

▼

Per CRMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001410098), CorMedix Inc. generated $311.7M in revenue (+617.0% YoY), $163.1M in net income, and $172.8M in free cash flow against $826.1M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (88.5% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.33 (-1.15%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 55.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY • 53.1% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE+0.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CRMD)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (59/100 Composite)

🔍 WHY CRMD SCORES 59/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 55.4% FCF Margin ($172.8M FCF) & 88.5% Gross Margin

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+15/20 pts (25% of score)

SEC Form 4 / 13F Thermometer: 75% Net Buy • Cannibal Buyback (-2.08% YoY Shares)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$7.39+2.4% Next Q

Q2 (-2Q)

Grade C+$7.57+5.7% Next Q

Q3 (-1Q)

Grade C+$8.00-32.6% Next Q

Current

Grade C-$5.39+0.2% Hist 90D α

Trajectory: B- (67) → C- (59)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the CRMD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 59/100 (C-) score, CRMD faces multiple-compression risk if 3.7x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 86.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($7.74) or 200D SMA ($7.67) invalidates the momentum regime and cuts Target Base ($5.41) toward Bear Floor ($4.22).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CRMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CRMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 59%NO 41%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (CRMD)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for CRMD.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating CRMD & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on CRMD
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CRMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -31.77%▼ SUPPORT BREAKDOWN

2026-11-03O $7.64H $7.64L $5.39C $5.39VOL 7.02M

RES: $8.32SUP: $6.35SMA50: $7.74SMA200: $7.67

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CRMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CRMD Butterfly Map → + Track CRMD →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

-15.0%/yr Implied 5Y Growth

vs. +617.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CRMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CRMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CRMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CRMD)

Health Care Rank #173 of 1016 ⚔️ KMDA vs CRMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CRMD vs. KMDA, BLSM, PRTA, PHAT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, CorMedix Inc. (CRMD) ranks #173 by composite RQD confidence (59/100, grade C-) and #463 by equity capitalization ($443.9M). Within this direct 5-issuer industry benchmark cohort, CRMD leads on earnings valuation at 3.7x trailing P/E, while CRMD leads on capital efficiency and profitability with 45.5% ROIC and 88.5% gross margin. CRMD currently leads its immediate peer cohort in composite quantitative strength at 59/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CRMD ACTIVE CorMedix Inc.	C-	59/100	3.7x	88.5%	45.5%	-5.36%	$443.9M	Benchmark Subject
KMDA Kamada Ltd.	D	46/100	—	—	—	-4.42%	$444.4M	/kmda-vs-crmd →
BLSM BlossomHill Therapeutics Inc.	D-	42/100	—	—	—	-9.67%	$437.0M	/blsm-vs-crmd →
PRTA Prothena Corporation plc	E	23/100	—	—	-35.0%	-2.12%	$434.8M	/prta-vs-crmd →
PHAT Phathom Pharmaceuticals Inc.	E	33/100	—	87.1%	-35.0%	+3.05%	$466.6M	/phat-vs-crmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001410098 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), CorMedix Inc. (CRMD) reported GAAP revenue of $311.7M (+617.0% vs. FY2024 revenue of $43.5M , and +127.4% cumulative change since FY2023) , GAAP net income of $163.1M, operating cash flow of $175.0M, and free cash flow of $172.8M (+440.6% YoY). On the balance sheet, CRMD closed FY2025 with $826.1M in total assets against $0 in total debt (Altman Z-Score: 1.81, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$311.7M	$163.1M	$175.0M	$172.8M	$826.1M	—
FY2024 (FY)	2024-12-31	$43.5M	-$17.9M	-$50.6M	-$50.7M	$118.8M	—
FY2023 (FY)	2023-12-31	$137.1M	-$46.3M	-$38.4M	-$38.4M	—	—

3. CRMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CRMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CRMD compare to KMDA and BLSM in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CRMD?

Where is CRMD trading relative to its 50-day, 200-day, and 52-week technical levels?

CRMD last traded at $5.39 (-5.36% on volume of 3,304,345 shares), positioning the stock -30.36% below its 50-day simple moving average ($7.74) and -29.73% below its 200-day simple moving average ($7.67). Across its 52-week range of $5.63 to $13.02, CRMD sits at the 0.0% percentile with a 14-day RSI of 37.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.72 to $6.06).

Direct Sub-Reports: CRMD RQD Cockpit CRMD 12M Forecast CRMD Earnings & Move CRMD Dividends & DRIP CRMD Insiders & 13F CRMD Whale Options CRMD Profit Sankey CRMD News & Why

ROARABLE RATING BRIEF • RQD 59/100 (C-) ✓ SEC XBRL & RQD VERIFIED

CRMD — CorMedix Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

CorMedix Inc. (CRMD) earns a live Roarable RQD composite score of 59/100, corresponding to a C- letter grade (Roarable Hold) at a spot price of $5.39 (-5.36% 1D, market capitalization $443.9M).

Fundamental Cash Engine (16/20): Anchored by return on invested capital (ROIC) of 45.5%, gross margin of 88.5%, operating margin of 48.2%, and free cash flow yield of —.
Whale 13F & Options Flow (4/20) + Insider Conviction (15/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (10/20) + Forensic Balance Sheet (14/20): Incorporates a 1.00x equity beta, Altman Z-Score of 1.81, Piotroski F-Score of 8/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

CorMedix Inc. Is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Pharmaceutical Preparations. The profile identifies the company by sector, industry, exchange, and market capitalization of $0.6B. Gross margin is reported at 88.5%, operating margin at 48.2%, and net margin at 52.3%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), CorMedix Inc. (CRMD) reported $311.7M in annual revenue (up from $43.5M in FY2024, +617.0% YoY) and $163.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($137.1M revenue, -$46.3M net income) through FY2025, CRMD scaled operating cash flow to $175.0M and free cash flow to $172.8M, backed by $826.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (C- • RQD 59/100): Strong cash generator (88.5% gross margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 16/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $5.63 – $13.02 52-week range.
🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 3.7x trailing P/E and 3.0x EV/EBITDA against 48.2% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. The one ripple the news wire does point to is reimbursement: the DaVita warning on 2027 DefenCath reimbursement implies that payer-side pricing decisions could transmit into the company's revenue, and an investor should monitor reimbursement announcements as the primary second-order channel.

Key Question #1: Can CRMD sustain or expand its 48.2% operating margin and 45.5% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $311.7M and free cash flow of $172.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is CRMD's 3.5x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CRMD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for CorMedix Inc. (CRMD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CRMD Debate Forum (3) ↓

🔴 RISK WATCH Yahoo Finance • 20h ago

CRMD Stock Hits Fresh 52-Week Low On DaVita’s Warning Of Sharp 2027 DefenCath Reimbursement Drop

Yahoo Finance report covering CorMedix Inc. (CRMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 23h ago

Cormedix Rezzayo label expansion under FDA review (CRMD:NASDAQ)

Seeking Alpha report covering CorMedix Inc. (CRMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?

Yahoo Finance report covering CorMedix Inc. (CRMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST kalkine.ca • 1d ago

CorMedix (NASDAQ: CRMD) Strengthens Its Commercial Growth Story

kalkine.ca report covering CorMedix Inc. (CRMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

CorMedix (NASDAQ:CRMD) Reaches New 1-Year Low - Here's Why

MarketBeat report covering CorMedix Inc. (CRMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Simply Wall St • 1d ago

With EPS Growth And More, CorMedix (NASDAQ:CRMD) Makes An Interesting Case

Simply Wall St report covering CorMedix Inc. (CRMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A weekly antifungal is under priority review to prevent fungal disease during stem-cell transplants

Stock Titan report covering CorMedix Inc. (CRMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Globe and Mail • 1d ago

Analysts Offer Insights on Healthcare Companies: Olympus (OtherOCPNF), IQVIA Holdings (IQV) and Cormedix (CRMD)

The Globe and Mail report covering CorMedix Inc. (CRMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CRMD Bull vs. Bear Conversation Board — What's Your Call at $5.39?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CRMD 🐻 33% BEARISH CONVICTION

CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $6.95 (+21.9%)

📌 Pinned Debate

Reported FY 2025 operating income of $150.1M and ROIC of 45.5% show strong earnings power against a $595.5M market cap.

Picked up a starter position in CRMD in my $100K Virtual Cash book at $5.70. Reported FY 2025 operating income of $150.1M and ROIC of 45.5% show strong earnings power against a $595.5M market cap.. Trading inside a $5.63–$13.02 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

RetailWhale_TX 🐂 BULL

@FadeTheHype Shorting a 4/20 institutional whale-flow stock at $5.70 is dangerous when funds are rotating into Health Care.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $4.79 (-16.0%)

Spot @ $5.70

The stock hit a fresh 52-week low on a DaVita warning of a sharp 2027 DefenCath reimbursement drop.

Here is the bear case nobody on the bull side wants to address on CRMD: The stock hit a fresh 52-week low on a DaVita warning of a sharp 2027 DefenCath reimbursement drop.. At 3.7x trailing P/E, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.